4D Molecular Therapeutics, Inc.
NASDAQ:FDMTBiotechnology
+$0.16 today
- Market cap
- $577.85M
- Beta
- 2.76
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$2.36
Volume 0.68M
Average 0.77M
FDMT Account Payables
Amounts the company owes suppliers for goods and services received.
4D Molecular Therapeutics, Inc.NASDAQ: FDMT
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 253.9% from a year ago
Account payables stood at $14.69M at the end of Q1 FY2026, up 253.9% from a year earlier and up 31.7% from the prior quarter. Over 3 fiscal years it compounded at +49.8% a year.
Context
- Account payables amounted to 2.9% of total assets at the end of Q1 FY2026, up 2.1 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +253.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 11.16M USD
- Year-over-year change
- +154.4%
- 4-year CAGR
- +23.7%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.16M | +154.4% |
| FY2024 | 2024-12-31 | 4.39M | +24.8% |
| FY2023 | 2023-12-31 | 3.52M | +5.8% |
| FY2022 | 2022-12-31 | 3.32M | -30.3% |
| FY2021 | 2021-12-31 | 4.76M | — |
Account Payables vs competitors
How FDMT compares with its peers on the latest reported figures
- FDMT's Mar 2026 account payables of $14.69M is the 3rd highest of the 8 companies compared; the peer median is $4.4M.
- Its year-over-year change of +253.9% is the highest of 8, against a peer median of -16.5%.
- Account payables amounts to 2.9% of total assets for FDMT, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $21.21M | +11.4% | -7.8% | 6.2% | |
| Mar 2026 | $16.66M | -17.9% | -15.4% | 6.8% | |
| Mar 2026 | $14.69M | +253.9% | +49.8% | 2.9% | |
| Mar 2026 | $5.56M | -13.6% | -0.1% | 1.3% | |
| Mar 2026 | $4.4M | -16.5% | -22.2% | 0.6% | |
| Mar 2026 | $4.07M | -18.9% | +63.3% | 2.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $3.34M | -72.2% | +21.9% | 1.3% |
| Mar 2026 | $3.24M | +0.5% | -8.4% | 5.7% | |
| Peer median (excluding FDMT) | $4.4M | -16.5% | -7.8% | 2.1% | |
Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 153M | 52.35M | 249.11M | 149.34M | 60.24M |
| Short-term Investments | 94.78M | 161.2M | 39.12M | 275.54M | 342.41M |
| Net Receivables | 47K | 700K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.46M | 6.26M | 8.36M | 10.06M | 10.48M |
| Total Current Assets | 256.28M | 220.51M | 296.59M | 434.93M | 413.13M |
| Property, Plant & Equipment (Net) | 28.95M | 35.35M | 31.67M | 40.61M | 33.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 67.65M | 4.91M | 10.95M | 80.58M | 111.38M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 602K | 1.08M | 684K | 4.26M | 9.19M |
| Total Non-current Assets | 97.21M | 41.34M | 43.3M | 125.45M | 153.58M |
| Total Assets | 353.49M | 261.85M | 339.89M | 560.38M | 566.71M |
| Account Payables | 4.76M | 3.32M | 3.52M | 4.39M | 11.16M |
| Short-term Debt | 0 | 2.66M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.6M | 884K | 273K | 257K | 360K |
| Other Current Liabilities | 0 | 3.18M | 3.87M | 0 | 0 |
| Total Current Liabilities | 16.34M | 15.73M | 18.95M | 29.15M | 43.99M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 2.49M | 1.08M | 972K | 1.06M | 745K |
| Other Non-current Liabilities | 334K | 233K | 617K | 603K | 496K |
| Total Non-current Liabilities | 18.04M | 14.78M | 13.11M | 20.63M | 17.06M |
| Total Liabilities | 34.38M | 30.51M | 32.06M | 49.78M | 61.05M |
| Common Stock | 3K | 3K | 4K | 5K | 6K |
| Retained Earnings | (207M) | (314.49M) | (415.33M) | (576.2M) | (716.3M) |
| Accumulated OCI | (423K) | (1.2M) | 16K | 229K | 727K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 319.11M | 231.34M | 307.83M | 510.61M | 505.66M |
| Total Debt | 16.45M | 16.12M | 14.67M | 24.61M | 21.41M |
| Net Debt | (136.55M) | (36.23M) | (234.44M) | (124.73M) | (38.83M) |
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
Intrinsic Alpha fair value
Locked
Current Price
$10.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.